LifeStance Health Group, Inc. Cash and Equivalents

Quick Answer

LifeStance Health Group, Inc. reported Cash and Equivalents of $248.64 million for fiscal year 2025.

LifeStance Health Group, Inc. Cash and Equivalents — Annual History

Fiscal Year Cash and Equivalents YoY Change
2025 $248.64M +60.9%
2024 $154.57M +96.1%
2023 $78.82M -27.4%
2022 $108.62M -26.6%
2021 $148.03M +686.2%
2020 $18.83M

Quarterly Cash and Equivalents

Quarter Ending Cash and Equivalents YoY QoQ
September 30, 2025 $203.90M +98.7% +7.9%
June 30, 2025 $188.93M +117.2% +40.6%
March 31, 2025 $134.34M +171.7% -13.1%
December 31, 2024 $154.57M +96.1% +50.6%
September 30, 2024 $102.61M +140.9% +18.0%
June 30, 2024 $86.97M +9.3% +75.9%
March 31, 2024 $49.45M -27.6% -37.3%
December 31, 2023 $78.82M -27.4% +85.0%
  • LifeStance Health Group, Inc. showed an increase of +60.9% in Cash and Equivalents compared to the prior fiscal year.
  • Over the 2020–2025 period, LifeStance Health Group, Inc.’s cash and equivalents has grown by 1220.5% (from $18.83 million to $248.64 million).
  • The most recent figure is from LifeStance Health Group, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 25, 2026.
  • All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.

Last verified:

Leave a Comment